Brokers Set Expectations for ZNTL Q3 Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - HC Wainwright issued their Q3 2025 EPS estimates for Zentalis Pharmaceuticals in a research report issued on Friday, November 15th. HC Wainwright analyst A. Fein anticipates that the company will earn ($0.67) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $20.00 target price on the stock. The consensus estimate for Zentalis Pharmaceuticals' current full-year earnings is ($2.76) per share. HC Wainwright also issued estimates for Zentalis Pharmaceuticals' Q4 2025 earnings at ($0.68) EPS.

A number of other research analysts have also recently weighed in on ZNTL. Guggenheim dropped their price objective on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a "buy" rating for the company in a report on Friday. Oppenheimer reaffirmed an "outperform" rating and set a $20.00 price objective on shares of Zentalis Pharmaceuticals in a report on Monday, September 16th. Finally, Wedbush raised shares of Zentalis Pharmaceuticals from an "underperform" rating to a "neutral" rating and set a $4.00 target price for the company in a report on Monday, August 12th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Zentalis Pharmaceuticals has an average rating of "Hold" and a consensus target price of $10.00.

Zentalis Pharmaceuticals Stock Performance

Shares of NASDAQ ZNTL traded down $0.42 during midday trading on Monday, reaching $3.05. 1,470,923 shares of the stock were exchanged, compared to its average volume of 1,330,244. The stock has a market capitalization of $217.34 million, a P/E ratio of -1.22 and a beta of 1.74. Zentalis Pharmaceuticals has a twelve month low of $2.66 and a twelve month high of $18.07. The company has a 50 day simple moving average of $3.42 and a 200 day simple moving average of $5.33.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.36.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ZNTL. ProShare Advisors LLC raised its holdings in shares of Zentalis Pharmaceuticals by 9.0% during the first quarter. ProShare Advisors LLC now owns 15,436 shares of the company's stock valued at $243,000 after acquiring an additional 1,274 shares during the period. Values First Advisors Inc. grew its position in shares of Zentalis Pharmaceuticals by 5.4% in the second quarter. Values First Advisors Inc. now owns 74,925 shares of the company's stock valued at $306,000 after purchasing an additional 3,859 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in Zentalis Pharmaceuticals by 63.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company's stock worth $50,000 after buying an additional 5,333 shares during the period. Carson Advisory Inc. raised its stake in Zentalis Pharmaceuticals by 55.8% during the 3rd quarter. Carson Advisory Inc. now owns 24,570 shares of the company's stock valued at $90,000 after purchasing an additional 8,800 shares during the last quarter. Finally, Anfield Capital Management LLC acquired a new stake in Zentalis Pharmaceuticals during the second quarter worth about $40,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.